prolactinoma

Summary

Summary: A pituitary adenoma which secretes PROLACTIN, leading to HYPERPROLACTINEMIA. Clinical manifestations include AMENORRHEA; GALACTORRHEA; IMPOTENCE; HEADACHE; visual disturbances; and CEREBROSPINAL FLUID RHINORRHEA.

Top Publications

  1. ncbi Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists
    D Kojo Hamilton
    Department of Neurosurgery, University of Virginia, Charlottesville, USA
    Pituitary 8:53-60. 2005
  2. ncbi Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up
    Gerald Raverot
    Institut National de la Sante et de la Recherche Medicale, Unité 842, Universite de Lyon, Lyon 1, Unité Mixte de Recherche UMR S842, Faculté de médecine Lyon Est, F 69372 Lyon, Cedex 08, France
    J Clin Endocrinol Metab 95:1708-16. 2010
  3. ncbi Advances in the treatment of prolactinomas
    Mary P Gillam
    Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Endocr Rev 27:485-534. 2006
  4. ncbi Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1Burin) in four kindreds from Newfoundland
    S E Olufemi
    Laboratory of Gene Transfer, National Human Genome Research Institute, NIH, Bethesda, Maryland 20892 4442, USA
    Hum Mutat 11:264-9. 1998
  5. doi Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline
    Shlomo Melmed
    Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 96:273-88. 2011
  6. doi Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients
    J Kreutzer
    Department of Neurosurgery, University of Erlangen Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany
    Eur J Endocrinol 158:11-8. 2008
  7. ncbi Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis
    Olaf M Dekkers
    Department of Endocrinology and Metabolic Diseases, C4 R, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    J Clin Endocrinol Metab 95:43-51. 2010
  8. ncbi Clinical practice. Prolactinoma
    Janet A Schlechte
    Department of Internal Medicine, University of Iowa, Iowa City, USA
    N Engl J Med 349:2035-41. 2003
  9. pmc Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists
    Muriel Babey
    Department of Neurosurgery, University of Berne, Inselspital, 3010, Berne, Switzerland
    Pituitary 14:222-30. 2011
  10. doi A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report
    Mineko Murakami
    Department of Neurosurgery, Teikyo University Chiba Medical Center, Ichihara City, Chiba, Japan
    Neurosurgery 68:E1761-7; discussion E1767. 2011

Research Grants

  1. REGULATION OF PROLACTIN SECRETION AT THE LACTOTROPH
    JOEL TABAK SZNAJDER; Fiscal Year: 2010
  2. ROLE AND REGULATION OF GALANIN IN PITUITARY ADENOMAS
    James Hyde; Fiscal Year: 1993
  3. GENERAL CLINICAL RESEARCH CENTER
    Gerard Burrow; Fiscal Year: 1990
  4. VIP AND ESTROGEN-INDUCED PROLACTINOMAS
    Diana Maas; Fiscal Year: 1993
  5. LONG TERM OUTCOME OF PITUITARY SURGERY FOR PROLACTINOMA
    Robert Adler; Fiscal Year: 2000
  6. PITUITARY TUMORS--PATHOGENESIS AND CELLULAR FUNCTION
    THOMAS CROXTON; Fiscal Year: 1990
  7. PITUITARY TUMORS--PATHOGENESIS AND CELLULAR FUNCTION
    THOMAS CROXTON; Fiscal Year: 1993
  8. HUMAN PROLACTINOMAS
    AMBER OCHOA; Fiscal Year: 1999
  9. FETAL ALCOHOL EXPOSURE AND TUMORIGENESIS
    Zehava Gottesfeld; Fiscal Year: 1990
  10. REGULATION OF PROLACTIN SECRETION AT THE LACTOTROPH
    JOEL TABAK SZNAJDER; Fiscal Year: 2010

Detail Information

Publications220 found, 100 shown here

  1. ncbi Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists
    D Kojo Hamilton
    Department of Neurosurgery, University of Virginia, Charlottesville, USA
    Pituitary 8:53-60. 2005
    Surgery for prolactinoma patients is usually reserved for those who are intolerant of or have an inadequate response to medication. We report the results of surgical treatment in these patients.
  2. ncbi Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up
    Gerald Raverot
    Institut National de la Sante et de la Recherche Medicale, Unité 842, Universite de Lyon, Lyon 1, Unité Mixte de Recherche UMR S842, Faculté de médecine Lyon Est, F 69372 Lyon, Cedex 08, France
    J Clin Endocrinol Metab 95:1708-16. 2010
    ..Predicting pituitary tumor behavior remains a challenge. This multiparameter investigation aimed to identify markers for recurrence and progression in prolactin tumors...
  3. ncbi Advances in the treatment of prolactinomas
    Mary P Gillam
    Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Endocr Rev 27:485-534. 2006
    ....
  4. ncbi Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1Burin) in four kindreds from Newfoundland
    S E Olufemi
    Laboratory of Gene Transfer, National Human Genome Research Institute, NIH, Bethesda, Maryland 20892 4442, USA
    Hum Mutat 11:264-9. 1998
    ..5 Mb region. A nonsense mutation in the MEN1 gene has been found to be responsible for the disease in the affected members in all four of the MEN1Burin families, providing convincing evidence of a common founder...
  5. doi Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline
    Shlomo Melmed
    Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 96:273-88. 2011
    ..The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia...
  6. doi Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients
    J Kreutzer
    Department of Neurosurgery, University of Erlangen Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany
    Eur J Endocrinol 158:11-8. 2008
    ..Classical' surgical indications are intolerance or lack of efficiency of DA therapy. Focusing on a possible shift of recent indications, we retrospectively analyzed our results of surgical treatment in prolactinomas...
  7. ncbi Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis
    Olaf M Dekkers
    Department of Endocrinology and Metabolic Diseases, C4 R, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    J Clin Endocrinol Metab 95:43-51. 2010
    ..Dopamine agonists are the treatment of choice for prolactinomas and symptomatic idiopathic hyperprolactinemia. However, the optimal treatment strategy and treatment duration is not clear in all details...
  8. ncbi Clinical practice. Prolactinoma
    Janet A Schlechte
    Department of Internal Medicine, University of Iowa, Iowa City, USA
    N Engl J Med 349:2035-41. 2003
  9. pmc Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists
    Muriel Babey
    Department of Neurosurgery, University of Berne, Inselspital, 3010, Berne, Switzerland
    Pituitary 14:222-30. 2011
    ..guidelines recommend long-term dopamine agonist (DA) therapy as a first-line approach to the treatment of small prolactinoma, some patients continue to prefer a primary surgical approach...
  10. doi A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report
    Mineko Murakami
    Department of Neurosurgery, Teikyo University Chiba Medical Center, Ichihara City, Chiba, Japan
    Neurosurgery 68:E1761-7; discussion E1767. 2011
    The case presented here describes the clinical evolution of a pituitary carcinoma from an atypical prolactinoma after temozolomide (TMZ) treatment. The mechanism of acquisition of TMZ resistance was analyzed.
  11. pmc Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma
    Eun Hee Cho
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    J Korean Med Sci 24:874-8. 2009
    Although cabergoline is effective in the treatment of micro- and macro-prolactinoma, little is known about its efficacy in the treatment of invasive giant prolactinoma...
  12. ncbi Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours
    F A Howe
    CRC Biomedical Magnetic Resonance Research Group, Department of Biochemistry and Immunology, St George s Hospital Medical School, London SW17 ORE, UK
    NMR Biomed 14:497-506. 2001
    ..We have measured the R(2)* changes in a prolactinoma tumour model for a variety of vasoactive challenges [carbogen, 100% oxygen and 100% nitrogen as different ..
  13. ncbi Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists
    Lisa M Neff
    Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Tufts New England Medical Center, Boston, MA 02111, USA
    Pituitary 10:81-6. 2007
    ..In this report, we describe a patient with an invasive prolactinoma resistant to conventional therapy that responded to the administration of the alkylating agent, temozolomide.
  14. ncbi Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up
    A Colao
    Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita Federico II di Napoli, Naples, Italy
    J Clin Endocrinol Metab 83:2777-80. 1998
    ..we report the clinical presentation, response to medical treatment, and long-term follow-up of 26 patients with prolactinoma (15 macro- and 11 micro-adenomas) diagnosed at the age of 7-17 yr...
  15. ncbi Giant prolactinomas: clinical management and long-term follow up
    Raj K Shrivastava
    Department of Neurosurgery, Mount Sinai Medical Center, New York, New York 10029, USA
    J Neurosurg 97:299-306. 2002
    ..Giant prolactinomas are rare tumors whose treatment and outcome has only been addressed in isolated case reports. The authors document the long-term follow-up findings and clinical outcome in a group of patients with giant prolactinomas...
  16. ncbi Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men
    Ilan Shimon
    Institute of Endocrinology and Metabolism, Rabin Medical Center, Beilinson Hospital, Petah Tiqwa, Israel
    Eur J Endocrinol 156:225-31. 2007
    ..To review our experience with cabergoline, a D2-selective dopamine agonist, for the treatment of giant prolactinomas...
  17. ncbi Multiple endocrine neoplasia type 1 variant with frequent prolactinoma and rare gastrinoma
    Wei Hao
    Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Endocrinol Metab 89:3776-84. 2004
    ..Results in cases from two kindreds were that 93% showed parathyroid adenoma, 40% pituitary tumor (always prolactinoma), and 27% enteropancreatic endocrine tumor...
  18. ncbi Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas
    A Bhansali
    Departments of Endocrinology, Postgraduate Institute of Medical Education and Research Chandigarh, India
    Indian J Med Res 131:530-5. 2010
    ..This possibly results in delayed normalization of serum prolactin and slow reduction in tumour size. This study was planned to assess the efficacy and safety of rapid escalation of cabergoline doses in men with macroprolactinomas...
  19. ncbi Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery
    Arun P Amar
    Department of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, USA
    J Neurosurg 97:307-14. 2002
    ....
  20. ncbi Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma
    S Cannavo
    Cattedra di Endocrinologia, Universita di Messina, Italy
    J Endocrinol Invest 22:354-9. 1999
    ..In conclusion, this study confirms the effectiveness and safety of CAB for patients with PRL-secreting pituitary adenoma and suggests that it can be considered a first choice treatment...
  21. doi Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via S Pansini 5, 80131 Napoli, Italy
    J Clin Endocrinol Metab 93:3777-84. 2008
    ..Cabergoline, a dopamine receptor-2 agonist used to treat prolactinomas, was associated with increased risk of cardiac valve disease in Parkinson's disease...
  22. ncbi Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma
    Annamaria Colao
    Department of Clinical and Molecular Endocrinology and Oncology, University Federico II of Naples, 80131 Naples, Italy
    J Clin Endocrinol Metab 89:2770-5. 2004
    ..prostate enlargement in humans, we designed this open, prospective, case-control study enrolling 20 men with prolactinoma (aged 34 +/- 10 yr) and 20 age-matched healthy men...
  23. ncbi Metastatic prolactinoma presenting as a cervical spinal cord tumour in multiple endocrine neoplasia type one (MEN-1)
    Michelle V Gordon
    Clin Endocrinol (Oxf) 66:150-2. 2007
  24. ncbi Cabergoline treatment of pregnant women with macroprolactinomas
    M Laloi-Michelin
    AP HP, Hopital Lariboisiere, Service de médecine interne B, Paris, France
    Int J Gynaecol Obstet 99:61-2. 2007
  25. pmc Progression on metastatic neuroendocrine carcinoma from a recurrent prolactinoma: a case report
    M Sironi
    Department of Pathology, Legnano General Hospital, Legnano, Milano, Italy
    J Clin Pathol 55:148-51. 2002
    ..The patient was known in the department because of previous multiple surgery for a locally invasive pituitary prolactinoma (eight years, three years, and one year previously)...
  26. ncbi Body fat in nonobese women with prolactinoma treated with dopamine agonists
    Erika C O Naliato
    Division of Endocrinology, Department of Internal Medicine, Federal University of Rio de Janeiro, Hyperprolactinemia Unit, Clementino Fraga Filho University Hospital, Rio de Janeiro, Brazil
    Clin Endocrinol (Oxf) 67:845-52. 2007
    To evaluate body fat in nonobese women with prolactinoma treated with dopamine agonists, using whole body dual energy X-ray absorptiometry (DXA) and to correlate DXA results with biochemical data and clinical aspects of the prolactinoma.
  27. ncbi Prolactinoma in some Ménière's patients--is stress involved?
    Kathleen C Horner
    Laboratoire d Otologie, Hopital Nord, Marseille, France
    Neuropsychopharmacology 26:135-8. 2002
    ..The presence of prolactinoma was confirmed by MRI in six cases out of six investigated and the others have not yet been followed up in this ..
  28. ncbi Gene expression study of thyrotropin releasing hormone (TRH) receptor using RT-PCR: relationship to clinical and immunohistochemical phenotypes in a series of human pituitary adenomas
    Junko Igarashi-Migitaka
    Department of Anatomy, St Marianna University School of Medicine, Sugao, Kawasaki 216 8511, Japan
    Endocr J 50:459-67. 2003
    ..It should be noted that the PRL response to TRH in prolactinoma or an abnormal response of gonadotropin and/or its subunits to TRH in gonadotroph cell adenomas is considered ..
  29. ncbi Malignant prolactinoma: case report and review of the literature
    Marleen Kars
    Department of Endocrinology, Leiden University Medical Center, Albinusdreef 2, PO Box 9600, 2300 RC Leiden, The Netherlands
    Eur J Endocrinol 155:523-34. 2006
    ..In addition, we reviewed all available literature on published cases of malignant prolactinoma and detailed their epidemiological, clinical, and histopathological characteristics...
  30. ncbi Endocrinological outcome following first time transsphenoidal surgery for GH-, ACTH-, and PRL-secreting pituitary adenomas
    R A Kristof
    Department of Neurosurgery, University of Bonn, Bonn, Germany
    Acta Neurochir (Wien) 144:555-61; discussion 561. 2002
    ..To study remission rates and pituitary functions following transsphenoidal surgery of newly diagnosed GH-, ACTH-, and PRL-secreting pituitary adenomas...
  31. ncbi A case of postprandial cluster-like headache with prolactinoma: dramatic response to cabergoline
    Kiyoshi Negoro
    Headache 45:604-6. 2005
    ..Magnetic resonance images showed a pituitary tumor. Just after starting treatment with cabergoline, the headaches resolved completely and the patient has been absolutely free from such headache attacks for 2 years...
  32. ncbi Pathological changes after radiotherapy for primary pituitary carcinoma: a case report
    Hideomi Yamashita
    Department of Radiology, University of Tokyo Hospital, 7 3 1, Hongo, Bunnkyou ku, Tokyo 113 8655, Japan
    J Neurooncol 75:209-14. 2005
    ..We confirmed that necrosis but no apoptosis were coexistent in the cells post irradiation for pituitary carcinoma...
  33. ncbi First reported pediatric case of systemic lupus erythematosus associated with prolactinoma
    Peter D Reuman
    Pediatric Rheumatology and Clinical Research, Children s Hospital Medical Center, One Perkins Square, Akron, OH 44308, USA
    Arthritis Rheum 50:3616-8. 2004
    ..We present the first reported pediatric case of prolactinoma associated with SLE, in a 13-year-old white female...
  34. ncbi Pharmacologic resistance in prolactinoma patients
    Mark E Molitch
    Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, 303 E Chicago Avenue, Tarry 15 731, Chicago, IL 60611, USA
    Pituitary 8:43-52. 2005
    ..Reduction of endogenous estrogen, use of selective estrogen receptor modulators, and aromatase inhibitors are potential experimental approaches...
  35. ncbi Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of 'hook effect'
    Maria Fleseriu
    Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Neurooncol 79:41-3. 2006
    ..His prolactin was found to be 13,144 ng/ml in our lab after surgery confirming the diagnosis of invasive giant prolactinoma. The patient developed a complete right third, fourth and sixth nerve palsy postoperatively...
  36. ncbi Incidence of pituitary tumors in the human population of Croatia
    Milan Vrkljan
    Center for Clinical Neuroendocrinology and Pituitary Diseases, Department of Endocrinology, Diabetes and Metabolic Diseases, University Hospital Sestre Milosrdnice, University of Zagreb, Zagreb, Croatia
    Coll Antropol 30:157-61. 2006
    ..The patient's classification is based on regional (Mediterranean and continental region, 20 counties) and the state level. In our analysis we haven't found difference in incidence of tumors between Mediterranean and continental region...
  37. ncbi The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma
    Mary P Gillam
    Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University, The Feinberg Medical School, Chicago, Illinois 60611, USA
    J Clin Endocrinol Metab 87:4447-51. 2002
    ..Ultimately, further reduction in PRL on this therapy permitted endogenous testosterone production. Thus, novel pharmacological maneuvers may permit successful medical treatment of some patients with invasive macroprolactinomas...
  38. ncbi The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type
    Paweł Bolko
    Department of Endocrinology, Internal Diseases and Metabolism, Karol Marcinkowski University of Medical Sciences, Poznan, Poland
    Pol Arch Med Wewn 109:489-95. 2003
    b>Prolactinoma is the most frequent type of secreting pituitary tumours. In the treatment, pharmacotherapy with dopamine agonists is considered the first-line option...
  39. ncbi Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
    Felipe F Casanueva
    Department of Medicine, Endocrine Division, Santiago de Compostela University, Spain
    Clin Endocrinol (Oxf) 65:265-73. 2006
    ....
  40. ncbi Headache induced by dopamine agonists prescribed for prolactinoma: think SUNCT!
    A J Larner
    Walton Centre for Neurology and Neurosurgery, Fazakerley, Liverpool, UK
    Int J Clin Pract 60:360-1. 2006
    ..neuralgiform headache with conjunctival injection and tearing (SUNCT) syndrome may be associated with pituitary prolactinoma and may be induced by treatment of prolactinoma with dopamine agonists...
  41. doi Use of the Leksell gamma knife in the treatment of prolactinoma patients
    Jana Jezkova
    Third Department of Medicine, First Medical Faculty, Charles University, Prague, Czech Republic
    Clin Endocrinol (Oxf) 70:732-41. 2009
    ..Surgical and radiation treatment is also indicated in certain situations. We describe our 12-year experience in treating prolactinomas with the Leksell gamma knife (LGK)...
  42. ncbi [Cabergoline-induced tension pneumocephalus in a patient with giant invasive prolactinoma. Case report]
    J Castro-Castro
    Servicios de Neurocirugía, Complejo Hospitalario de Ourense, Ourense, Espana
    Neurocirugia (Astur) 22:558-61; discussion 561. 2011
    ..He had been treated for 2 weeks with cabergoline after an invasive prolactinoma was discovered...
  43. ncbi Effects of different levels of hypercapnic hyperoxia on tumour R(2)* and arterial blood gases
    S P Robinson
    CRC Biomedical Magnetic Resonance Research Group, Division of Biochemistry and Immunology, St George s Hospital Medical School, London, UK
    Magn Reson Imaging 19:161-6. 2001
    ..The data support the concept that levels of hypercapnia can be reduced without loss of enhanced oxygenation and hence potential radiotherapeutic benefit...
  44. pmc An Intronic mutation is associated with prolactinoma in a young boy, decreased penetrance in his large family, and variable effects on MEN1 mRNA and protein
    L Drori-Herishanu
    Section of Endocrinology and Genetics, Program on Developmental Endocrinology Genetics PDEGEN, NIH, Bethesda, Maryland 20892, USA
    Horm Metab Res 41:630-4. 2009
    Prolactinomas are rare tumors in prepubertal children. A prolactinoma in a young child may be due to sequence variants in genes that are known to cause these tumors ( MEN1, PRKAR1A, AIP)...
  45. ncbi Tumor tissue identification in the pseudocapsule of pituitary adenoma: should the pseudocapsule be removed for total resection of pituitary adenoma?
    Eun Jig Lee
    Division of Endocrinology, Pituitary Tumor Clinic, Yonsei University College of Medicine, Seoul, Korea
    Neurosurgery 64:ons62-9; discussion ons69-70. 2009
    ..We investigated the precise histology of the pseudocapsule. Furthermore, we evaluated the remission rate, the changes in pituitary function, and the recurrence rate after intensive resection of the pseudocapsule...
  46. ncbi Polycystic ovary syndrome and prolactinoma association
    Irfan Yavasoglu
    Adnan Menderes University Medical Faculty, Aydin, Turkey
    Intern Med 48:611-3. 2009
    ..with irregular menses, obesity, hirsutism and infertility, and hyperprolactinemia who was diagnosed as PCOS and prolactinoma and admitted to our clinic. Prolactinoma and PCOS association is a rare condition...
  47. ncbi Psoriasis in association with prolactinoma: three cases
    M Sánchez Regaña
    Department of Dermatology, Hospital Sagrado Corazon, University of Barcelona, C París 83 87 5th floor, 08029 Barcelona, Spain
    Br J Dermatol 143:864-7. 2000
    ..psoriasis in whom increase in severity and extent of the skin lesions correlated with the development of a prolactinoma. In all three patients, administration of bromocriptine, a dopamine agonist that suppresses the secretion of ..
  48. doi A novel use of temozolomide in a patient with malignant prolactinoma
    Stephen Byrne
    Department of Neurosurgery, Flinders Medical Centre, Flinders Drive, Bedford Park, South Australia 5042, Australia
    J Clin Neurosci 16:1694-6. 2009
    ..who presented to our department in 2007 with bitemporal hemianopia secondary to a large recurrent pituitary prolactinoma in the sellar region and metastatic deposits elsewhere in his neuraxis...
  49. ncbi Attenuated expression of menin and p27 (Kip1) in an aggressive case of multiple endocrine neoplasia type 1 (MEN1) associated with an atypical prolactinoma and a malignant pancreatic endocrine tumor
    Emi Ishida
    Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Japan
    Endocr J 58:287-96. 2011
    ..We describe the case of a 56 year-old male with an atypical prolactinoma and malignant pancreatic neuroenocrine tumor...
  50. doi Effects of estrogen receptor antagonist on biological behavior and expression of growth factors in the prolactinoma MMQ cell line
    Hongtao Lv
    Beijing Neurosurgical Institute, Capital Medical University, 6 Tiantan Xili, Chongwen District, Beijing, 100050, People s Republic of China
    J Neurooncol 102:237-45. 2011
    The relationship between estrogen and pituitary prolactinoma is well documented. The biological effects of estrogen are mainly mediated by estrogen receptor α (ERα)...
  51. doi Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy
    Katarina Berinder
    Department of Molecular Medicine and Surgery, Endocrine and Diabetes Unit, Karolinska Institutet, 171 76, Stockholm, Sweden
    Pituitary 14:199-207. 2011
    ..85, P = 0.034). In conclusion, beneficial metabolic changes were seen in prolactinoma patients after treatment with DA agonists, underscoring the importance of an active treatment approach and to ..
  52. ncbi Successful treatment of a large macroprolactinoma with cabergoline during pregnancy
    C Liu
    Department of Medicine, University of California, San Francisco, 94143 0326, USA
    Pituitary 4:179-85. 2001
    ..A 7 week pregnant woman with a history of a prolactinoma presented to the endocrine clinic with the complaints of headaches and nausea...
  53. ncbi Latent prolactinoma on MRI-selective venous sampling and trans-sphenoidal microsurgical treatment
    H Nakagawa
    Department of Neurosurgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan
    Neurol Res 23:691-6. 2001
    ..a correspondence of laterality of the peak prolactin level with the main tumor location in patients with latent prolactinoma. However, the tumor/nontumor ratio did not necessarily coincide with the pattern of tumor location, and tumor ..
  54. ncbi Prolactinomas and pregnancy
    Marcello Delano Bronstein
    Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clinicas, University of S Paulo Medical School, Av 9 de Julho 3858, 01406 100, S Paulo, SP, Brazil
    Pituitary 8:31-8. 2005
    ..Reintroduction of bromocriptine in such cases can lead to tumor reduction and clinical improvement. Surgery can also be employed as treatment for symptomatic tumor growth in pregnancy...
  55. ncbi Endoscopic approach to the pituitary lesions: contemporary method and review of the literature
    A Kuroki
    Department of Neurosurgery, Yamagata University School of Medicine, 2 2 2 Iida nishi, Yamagata 990 9585, Japan
    Biomed Pharmacother 56:158s-164s. 2002
    ..The overall result by endoscopic transsphenoidal surgery is as good as or better than that by the traditional microscopic transsphenoidal surgery...
  56. pmc Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy
    J Kharlip
    Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland 21201, USA
    J Clin Endocrinol Metab 94:2428-36. 2009
    ..Recurrence of hyperprolactinemia after cabergoline withdrawal ranges widely from 36 to 80%. The Pituitary Society recommends withdrawal of cabergoline in selected patients...
  57. ncbi Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lessons from long-term follow-up
    John A Thomson
    University Department of Medicine, Glasgow Royal Infirmary, Glasgow, Scotland G4 0SF, UK
    Neurosurgery 50:36-9; discussion 39-40. 2002
    ..The long-term results of transsphenoidal surgery for microprolactinoma, with particular reference to the question of permanence of relapse of hyperprolactinemia after biochemical cure, are examined...
  58. doi Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required
    M Kars
    Department of Endocrinology and Metabolic Diseases, C4 R, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    Eur J Endocrinol 159:363-7. 2008
    ..the safety of treatment with ergot-derived dopamine agonists in patients with endocrine diseases, especially prolactinoma. Six cross-sectional studies have been published recently, of which five studies do not show an association ..
  59. ncbi Bone density in women with prolactinoma treated with dopamine agonists
    Erika Cesar de Oliveira Naliato
    Division of Endocrinology, Department of Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
    Pituitary 11:21-8. 2008
    1) to evaluate bone density in women with prolactinoma treated with dopamine agonists and healthy controls, using dual energy x-ray absorptiometry (DXA), (2) to classify the results according to the current International Society for ..
  60. doi Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists
    Marleen Kars
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    Eur J Intern Med 20:387-93. 2009
    ..Dopamine agonists are the first line therapy for the treatment of prolactinomas. The aim of this study was to assess the outcome of macroprolactinomas during long-term follow-up after initial treatment with dopamine agonists...
  61. ncbi Pituitary abscess associated with prolactinoma
    Awadhesh Kumar Jaiswal
    Department of Neurosurgery, Neurosciences Centre, All India Institute of Medical Sciences, New Delhi 110029, India
    J Clin Neurosci 11:533-4. 2004
    ..She had an uneventful postoperative recovery. At 2 years follow up, she was doing well...
  62. doi BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists
    Cintia M Dos Santos Silva
    Division of Endocrinology, Hospital Universitário Clementino Fraga Filho Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
    Obesity (Silver Spring) 19:800-5. 2011
    ..objectives of this study were to determine the prevalence of obesity, overweight, MS, and IR in patients with prolactinoma before and after therapy with DA and to evaluate the relation between prolactin (PRL), body weight, fat ..
  63. doi Prolactinoma in children and adolescents
    H L Fideleff
    Endocrinology Unit, Department of Medicine, Hospital T Alvarez, Buenos Aires, Argentina
    Horm Res 72:197-205. 2009
    ..The diagnosis of prolactinoma requires both radiographic evidence of pituitary adenoma and laboratory analysis documenting the presence of ..
  64. doi Clinical profile and long term follow up of children and adolescents with prolactinomas
    Shrikrishna V Acharya
    K E M Hospital, Parel, Mumbai, 400012 Maharashtra, India
    Pituitary 12:186-9. 2009
    ..presentation, response to medical treatment, and long-term follow-up of 39 children and adolescents with prolactinoma (F:M; 30:9) (30 macro and 9 microadenoma) diagnosed at the age of 9-20 years...
  65. doi Hyperprolactinemia: different clinical expression in childhood
    L Saranac
    Pediatric Clinic, University Clinical Center, Nis, Serbia endoljilja yahoo com
    Horm Res Paediatr 73:187-92. 2010
    ..Hyperprolactinemia is the most common disturbance in pituitary gland secretion. Functional diversity of prolactin action is responsible for different initial clinical expressions of hyperprolactinemia...
  66. ncbi Pituitary tumours: the prolactinoma
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via S Pansini 5, 80131 Naples, Italy
    Best Pract Res Clin Endocrinol Metab 23:575-96. 2009
    ..The patients achieving disappearance of the tumours and suppression of PRL levels during treatment are those showing the highest likelihood to have persistent remission of hyperprolactinaemia after treatment withdrawal...
  67. ncbi High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium
    Adrian F Daly
    Department of Endocrinology, Centre Hospitalier Universitaire de Liege, Domaine Universitaire du Sart Tilman, 4000 Liege, Belgium
    J Clin Endocrinol Metab 91:4769-75. 2006
    ..Prevalence data are important for assessing the burden of disease on the health care system; data on pituitary adenoma prevalence are very scarce...
  68. ncbi Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma
    Marleen Kars
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, P O Box 9600, 2300 RC Leiden, The Netherlands
    J Clin Endocrinol Metab 93:3348-56. 2008
    ..The aim of the present study was to assess the prevalence of valvular heart disease in patients treated with dopamine agonists for prolactinomas...
  69. ncbi Nerve growth factor regulates dopamine D(2) receptor expression in prolactinoma cell lines via p75(NGFR)-mediated activation of nuclear factor-kappaB
    Chiara Fiorentini
    Division of Pharmacology, Department of Biomedical Sciences and Biotechnology, University of Brescia, 25123 Brescia, Italy
    Mol Endocrinol 16:353-66. 2002
    Two groups of prolactinoma cell lines were identified...
  70. ncbi Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas
    M Biswas
    Department of Endocrinology, University Hospital of Wales, Heath Park, Cardiff, Wales, UK
    Clin Endocrinol (Oxf) 63:26-31. 2005
    ..Subjects received dopamine agonist (DA) therapy with either cabergoline or bromocriptine for a period of 2 to 3 years in the majority of cases, followed by a trial of treatment withdrawal...
  71. ncbi Multiple endocrine neoplasia type 1
    Gerard M Doherty
    NW Thompson Professor of Surgery, University of Michigan, Ann Arbor, Michigan, USA
    J Surg Oncol 89:143-50. 2005
    ..Care of people with MEN-1 requires knowledge of the problems that may arise, and the best approaches to detect and care for the manifestations of this incurable, but manageable, disease...
  72. ncbi Can radiation induce pituitary tumors? Giant prolactinoma after radiation exposure
    Nilesh S Kurwale
    Cardio Neuro Centre, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110 029, India
    J Clin Neurosci 15:1287-8. 2008
    ..The role of radiation exposure in the etiology of pituitary adenoma is discussed, along with a literature review of radiation-induced tumors...
  73. doi Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
    Sophie Vallette
    Department of Endocrinology, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Sherbrooke East, Montreal, QC, H2L 4M1, Canada
    Expert Rev Cardiovasc Ther 8:49-54. 2010
    ..The clinical significance of the present findings has yet to be confirmed by future larger prospective studies with rigorous echocardiographic protocols and prolonged duration of follow-up...
  74. ncbi Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas
    X Zhang
    Cedars Sinai Research Institute University of California School of Medicine, Los Angeles 90048, USA
    J Clin Endocrinol Metab 84:761-7. 1999
    ..The ubiquitous and prevalent expression of pituitary adenoma PTTG suggests that PTTG plays a role in pituitary tumorigenesis and invasiveness...
  75. ncbi Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, Federico II University of Naples, Naples, Italy
    N Engl J Med 349:2023-33. 2003
    ..We performed an observational, prospective study of cabergoline (a dopamine-receptor agonist) withdrawal in such patients...
  76. pmc Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model
    Dominick J O McIntyre
    Department of Basic Medical Sciences, St George s Hospital Medical School, Tooting, London, UK
    Neoplasia 6:150-7. 2004
    ..This study investigated the duration of the response to the vascular targeting agent, ZD6126, of the GH3 prolactinoma, in which efficacy and dose-response have previously been demonstrated...
  77. ncbi Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases
    C Akkaya
    Medical Faculty, Psychiatry Department, Uludag University, Bursa, Turkey
    J Psychopharmacol 23:723-6. 2009
    ..Antipsychotics may enhance prolactinoma growth as manifested by an increase in serum prolactin concentration...
  78. ncbi Prevalence of osteopenia in men with prolactinoma
    E C O Naliato
    Department of Internal Medicine, Federal University of Rio de Janeiro UFRJ, Brazil
    J Endocrinol Invest 28:12-7. 2005
    ..study was to analyze bone mineral density (BMD) and prevalence of osteopenia and osteoporosis in 30 men with prolactinoma, and compare them to 22 control subjects...
  79. doi Difficulties in the medical treatment of prolactinoma in a patient with schizophrenia--a case report with a review of the literature
    Sarah Konopelska
    J Clin Psychopharmacol 28:120-2. 2008
  80. ncbi Malignant prolactinoma with multiple bone and pulmonary metastases. Case report
    Cristina Lamas
    Department of Endocrinology, Hospital Universitario Puerta de Hierro, Madrid, Spain
    J Neurosurg 101:116-21. 2004
    ..The authors describe a 14-year-old boy who presented with visual loss caused by a pituitary prolactinoma. He underwent transsphenoidal surgery, radiotherapy, and dopamine agonist therapy, but 6 years after the ..
  81. ncbi Late development of intraventricular papillary pituitary carcinoma after irradiation of prolactinoma
    Martha Lilia Tena-Suck
    Department of Neuropathology, National Institute of Neurology and Neurosurgery, Manuel Velasco Suarez, Delegación Tlalpan CP 14269, Mexico City, Mexico
    Surg Neurol 66:527-33; discussion 533. 2006
    ..Most of the cases have been reported as metastases from pituitary carcinoma. A case of papillary pituitary carcinoma developed 12 years after radiotherapy for prolactin-secreting hormone pituitary adenoma is presented...
  82. doi Aripiprazole reduces serum prolactin in a woman with prolactinoma and acute psychosis
    A J Sheldrick
    Pharmacopsychiatry 41:160. 2008
  83. doi Valvular heart disease and the use of cabergoline for the treatment of prolactinoma
    Neil Herring
    Department of Cardiovascular Medicine, John Radcliffe Hospital, Oxford University, Oxford, UK
    Clin Endocrinol (Oxf) 70:104-8. 2009
    ..The mitral valve tenting area, a subclinical index of leaflet stiffening, has also been correlated with the cumulative dose of cabergoline and severity of valvular regurgitation...
  84. ncbi Inhibitory effect of thalidomide on the growth, secretory function and angiogenesis of estrogen-induced prolactinoma in Fischer 344 rats
    Henryk Stepien
    Department of Immunoendocrinology, Medical University of Lodz, Dr Sterling 3 Street, 91 425 Lodz, Poland
    Life Sci 79:1741-8. 2006
    The process of angiogenesis has been found to be essential for the development of estrogen-induced pituitary prolactinoma in Fischer 344 rats...
  85. ncbi Nonsurgical cerebrospinal fluid rhinorrhea in invasive macroprolactinoma: incidence, radiological, and clinicopathological features
    S G I Suliman
    Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, Oxford OX3 7LJ, United Kingdom
    J Clin Endocrinol Metab 92:3829-35. 2007
    ..Macroprolactinomas (MPRLs) may result in nonsurgical (spontaneous or dopamine agonist induced) cerebrospinal fluid (CSF) rhinorrhea; however, the incidence of and mechanisms underlying this phenomenon are poorly understood...
  86. pmc Heregulin regulates prolactinoma gene expression
    George Vlotides
    Department of Medicine, Cedars Sinai Medical Center, University of California School of Medicine, Los Angeles, CA, USA
    Cancer Res 69:4209-16. 2009
    ..Targeted inhibition of up-regulated p185(c-neu)/ErbB3 activity could be useful for the treatment of aggressive prolactinomas resistant to conventional therapy...
  87. ncbi Cortistatin-17 and somatostatin-14 display the same effects on growth hormone, prolactin, and insulin secretion in patients with acromegaly or prolactinoma
    S Grottoli
    Division of Endocrinology and Metabolism, Department of Internal Medicine, San Giovanni Battista Molinette Hospital, Corso Dogliotti 14, 10126 Turin, Italy
    J Clin Endocrinol Metab 91:1595-9. 2006
    ..Cortistatin binds all somatostatin receptor subtypes but also has particular central actions; moreover, a specific cortistatin receptor has also been discovered...
  88. ncbi Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones
    Andreas Mueller
    Department of Obstetrics and Gynecology, Erlangen University Hospital, Universitaetsstr 21 23, D 91054 Erlangen, Germany
    Eur J Endocrinol 159:197-202. 2008
    ..Design Description of cases of transsexuals who have developed a hormone-related malignancy observed in their own clinic or reported in the literature. Recommendations for early diagnosis and prevention are presented...
  89. ncbi Metastatic prolactinoma: case report with immunohistochemical assessment for p53 and Ki-67 antigens
    Paulo S Crusius
    Institute of Neurology and Neurosurgery, Passo Fundo, RS, Brazil
    Arq Neuropsiquiatr 63:864-9. 2005
    ..In conclusion, p53 staining is not positive in all pituitary carcinomas. A high Ki-67 proliferative index in a pituitary adenoma might indicate a more aggressive behavior...
  90. ncbi Gender-related differences in prolactinomas. A clinicopathological study
    Bernhard Schaller
    corrected
    Neuro Endocrinol Lett 26:152-9. 2005
    ..Only few studies have documented gender-related differences in the growth and presentation of these tumors, but nothing is known about their effects on their subsequent surgical outcome and prognosis...
  91. ncbi Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice
    S L Asa
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Ontario, Canada
    Endocrinology 140:5348-55. 1999
    ..The unexpected development of adenomas in males without preexisting or concomitant hyperplasia suggests that prolonged loss of dopamine inhibition may also cause neoplasia by distinct cellular mechanisms in male and female animals...
  92. ncbi Late development of frontal prolactinoma after resection of pituitary tumor
    Jesus Vaquero
    Department of Neurosurgery, Neuroscience Research Unit of the Mapfre Medicine Foundation, Puerta de Hierro Clinic, Autonomous University, Madrid, Spain
    J Neurooncol 64:255-8. 2003
    The unusual case of a patient with a frontal lobe prolactinoma developed 14 years after resection of a histologically benign pituitary adenoma is presented...
  93. ncbi In vitro and in vivo herpetic vector-mediated gene transfer in the pituitary gland: impact on hormone secretion
    F Bolognani
    Institute for Biochemical Research of La Plata (INIBIOLP) Histology B, Faculty of Medicine, University of La Plata, Argentina
    Eur J Endocrinol 145:497-503. 2001
    ..In some oestrogen-induced prolactinoma-carrying rats, vector suspension was stereotaxically injected into the glands to assess transgene expression in ..
  94. pmc Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk
    Marcelo Paez-Pereda
    Max Planck Institute of Psychiatry, Kraepelinstrasse 10, 80804 Munich, Germany
    Proc Natl Acad Sci U S A 100:1034-9. 2003
    ..BMP-4 is overexpressed in other prolactinoma models, including estradiol-induced rat prolactinomas and human prolactinomas, compared with normal tissue and ..
  95. ncbi Dopaminergic D2 receptor knockout mouse: an animal model of prolactinoma
    Carolina Cristina
    Instituto de Biologia y Medicina Experimental CONICET, Vuelta de Obligado 1490, 1428 Buenos Aires, Argentina
    Front Horm Res 35:50-63. 2006
    ..The D2R knockout mouse represents a unique animal model to study dopamine-resistant prolactinomas, and VEGF-A may be an alternative therapeutic target in this pathology...
  96. ncbi Three-dimensional imaging of hormone-secreting cells and their microvessel environment in estrogen-induced prolactinoma of the rat pituitary gland by confocal laser scanning microscopy
    J Itoh
    Laboratories for Structure and Function Research, Tokai University, School of Medicine, Isehara, Kanagawa, Japan
    Appl Immunohistochem Mol Morphol 9:364-70. 2001
    ..three-dimensional imaging of hormone-secreting cells and their microvascular environment in estrogen-induced prolactinoma of the rat pituitary gland...
  97. ncbi Ovarian dependence for pituitary tumorigenesis in D2 dopamine receptor-deficient mice
    Shane T Hentges
    Vollum Institute, Oregon Health and Science University, Portland, Oregon 97201, USA
    Endocrinology 143:4536-43. 2002
    ..These findings illustrate the importance of genetic background when analyzing endocrine regulation in mutant mouse models...
  98. ncbi Estrogen receptors in prolactinomas: a clinico-pathological study
    G J Kaptain
    Department of Neurosurgery, University of Virginia Health Sciences Center, Charlottesville 22908, USA
    Pituitary 1:91-8. 1999
    ..The use of antiestrogen therapy in pituitary adenomas, however, has not been explored. This study attempted to identify a population who may benefit from antiestrogen therapy...
  99. ncbi CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas
    K S Leong
    University Clinical Department of Diabetes and Endocrinology, University Hospital Aintree, Liverpool, UK
    Clin Endocrinol (Oxf) 52:43-9. 2000
    ..Our objective was therefore to investigate the different treatments for this condition...
  100. ncbi Prolactinoma with preferential infrasellar extension: a report of two cases
    S Nishio
    Department of Neurosurgery, Neurological Institute, Faculty of Medicine, Kyushu University, Fukuoka, Japan
    J Clin Neurosci 8:287-9. 2001
    ..The authors thus emphasise the need to recognise this peculiar infrasellar growth pattern of prolactinoma.
  101. ncbi Giant prolactinomas in men: efficacy of cabergoline treatment
    S M Corsello
    Institute of Endocrinology, Catholic University School of Medicine, Rome, Italy
    Clin Endocrinol (Oxf) 58:662-70. 2003
    The term 'giant prolactinoma' can be used for tumours larger than 4 cm in diameter and/or with massive extrasellar extension...

Research Grants67

  1. REGULATION OF PROLACTIN SECRETION AT THE LACTOTROPH
    JOEL TABAK SZNAJDER; Fiscal Year: 2010
    ..For example, the benign hypersecreting pituitary tumor known as a prolactinoma is treated with the dopamine agonists bromocryptine or cabergoline...
  2. ROLE AND REGULATION OF GALANIN IN PITUITARY ADENOMAS
    James Hyde; Fiscal Year: 1993
    ..Estrogen has a profound stimulatory effect on prolactin synthesis and release. and induces prolactinoma formation in the rat...
  3. GENERAL CLINICAL RESEARCH CENTER
    Gerard Burrow; Fiscal Year: 1990
    ..and opiate receptor antagonists in both patients with hypothalamic hypogonadotropic amenorrhea and those with prolactinoma; however, patients with prepubertal gonadotropin levels failed to respond...
  4. VIP AND ESTROGEN-INDUCED PROLACTINOMAS
    Diana Maas; Fiscal Year: 1993
    ..rat model of diethylstilbestrol (DES)-induced tumors is an excellent model for the study of the mechanism of prolactinoma formation...
  5. LONG TERM OUTCOME OF PITUITARY SURGERY FOR PROLACTINOMA
    Robert Adler; Fiscal Year: 2000
    ..The two most common causes of pituitary adenomas are prolactinoma and clinically non-functioning tumors, where each comprises about 30-40% of all tumors...
  6. PITUITARY TUMORS--PATHOGENESIS AND CELLULAR FUNCTION
    THOMAS CROXTON; Fiscal Year: 1990
    ..of prolactin (PRL) a common cause of female infertility, is usually associated with an anterior pituitary prolactinoma. This study will characterize changes in the physiological mechanisms controlling PRL secretion that occur with ..
  7. PITUITARY TUMORS--PATHOGENESIS AND CELLULAR FUNCTION
    THOMAS CROXTON; Fiscal Year: 1993
    ..of prolactin (PRL) a common cause of female infertility, is usually associated with an anterior pituitary prolactinoma. This study will characterize changes in the physiological mechanisms controlling PRL secretion that occur with ..
  8. HUMAN PROLACTINOMAS
    AMBER OCHOA; Fiscal Year: 1999
    ..We recently identified two distinct cell populations in human prolactinoma cell cultures. The majority of cells are lactotrophs, as evident by their expression and release of prolactin...
  9. FETAL ALCOHOL EXPOSURE AND TUMORIGENESIS
    Zehava Gottesfeld; Fiscal Year: 1990
    ..which were exposed to alcohol in utero display increased susceptibility to estrogen-induced pituitary tumors (prolactinoma) and a further enhancement of immune suppression...
  10. REGULATION OF PROLACTIN SECRETION AT THE LACTOTROPH
    JOEL TABAK SZNAJDER; Fiscal Year: 2010
    ..For example, the benign hypersecreting pituitary tumor known as a prolactinoma is treated with the dopamine agonists bromocryptine or cabergoline...
  11. Attenuation of Estrogen-Induced Cell Proliferation
    DOUGLAS WENDELL; Fiscal Year: 2003
    ..Consequently, estrogen treatment of F344 rats induces uncontrolled cell proliferation and prolactinoma. Aim #1 of this project is to develop a primary cell culture system to investigate the effect of the BN allele ..
  12. PATHOPHYSIOLOGY AND MANAGEMENT OF PITUITARY TUMORS
    PHILIP CRYER; Fiscal Year: 2001
    This study assesses pathophysiology mechanism in patients with functioning pituitary tumors, especially prolactinoma and growth hormone secreting adenomas...
  13. PATHOPHYSIOLOGY AND MANAGEMENT OF PITUITARY TUMORS
    PHILIP CRYER; Fiscal Year: 2002
    This study assesses pathophysiology mechanism in patients with functioning pituitary tumors, especially prolactinoma and growth hormone secreting adenomas...
  14. PATHOPHYSIOLOGY AND MANAGEMENT OF PITUITARY TUMORS
    PHILIP CRYER; Fiscal Year: 2000
    This study assesses pathophysiology mechanism in patients with functioning pituitary tumors, especially prolactinoma and growth hormone secreting adenomas...
  15. PATHOPHYSIOLOGY AND MANAGEMENT OF PITUITARY TUMORS
    PHILIP CRYER; Fiscal Year: 1999
    This study assesses pathophysiology mechanism in patients with functioning pituitary tumors, especially prolactinoma and growth hormone secreting adenomas...
  16. LONG TERM OUTCOME OF PITUITARY SURGERY FOR PROLACTINOMA
    Robert Adler; Fiscal Year: 1999
    To determine the long term effects of transsphenoidal hypophysectomy for the treatment of prolactinoma as an alternative to life time treatment with dopamine agonists.
  17. LONG TERM OUTCOME OF PITUITARY SURGERY FOR PROLACTINOMA
    Robert Adler; Fiscal Year: 2001
    To determine the long term effects of transsphenoidal hypophysectomy for the treatment of prolactinoma as an alternative to life time treatment with dopamine agonists.
  18. LONG TERM OUTCOME OF PITUITARY SURGERY FOR PROLACTINOMA
    Robert Adler; Fiscal Year: 1999
    To determine the long term effects of transsphenoidal hypophysectomy for the treatment of prolactinoma as an alternative to life time treatment with dopamine agonists.
  19. PITUITARY-SPECIFIC ONCOGENE SIGNALING MECHANISMS
    Arthur Gutierrez Hartmann; Fiscal Year: 2009
    ..we propose to move our Ras work to a more translational level, and address the role of Ras/MAPK in pituitary prolactinoma tumor formation, and whether PTTG-1 and Menin act as downstream effectors in this pathway...
  20. NEURAL CONTROL MECHANISMS OF METABOLIC FUNCTIONS
    Seymour Reichlin; Fiscal Year: 1980
    ..In patients with prolactinoma detailed studies of the physiology of regulation are being carried out in order to determine more precise ways ..
  21. Post-DPP Follow-Up Study
    Mark Molitch; Fiscal Year: 2008
    ..women, and in older subjects in the DPP. The current application is for 5 years of funding, although the some of the goals of the projects described will require a 10-year study. ..
  22. Post-DPP Follow-Up Study
    Mark Molitch; Fiscal Year: 2007
    ..women, and in older subjects in the DPP. The current application is for 5 years of funding, although the some of the goals of the projects described will require a 10-year study. ..
  23. Fetal Alcohol Effects on Circadian clocks and POMC
    DIPAK SARKAR; Fiscal Year: 2007
    ..This information should help to develop therapeutic strategies in managing sleep-wake disturbances and the resultant health consequences in FAE offspring. [unreadable] [unreadable] [unreadable]..
  24. ALCOHOL AND HYPERPROLACTINEMIA
    DIPAK SARKAR; Fiscal Year: 2007
    ..Such knowledge will improve the understanding and management of hyperprolactinemia in alcoholic patients. ..
  25. Fetal Alcohol Effects on Circadian clocks and POMC
    DIPAK SARKAR; Fiscal Year: 2006
    ..This information should help to develop therapeutic strategies in managing sleep-wake disturbances and the resultant health consequences in FAE offspring. [unreadable] [unreadable] [unreadable]..
  26. ALCOHOL AND HYPERPROLACTINEMIA
    DIPAK SARKAR; Fiscal Year: 2006
    ..Such knowledge will improve the understanding and management of hyperprolactinemia in alcoholic patients. ..
  27. ALCOHOL AND HYPERPROLACTINEMIA
    DIPAK SARKAR; Fiscal Year: 2005
    ..Such knowledge will improve the understanding and management of hyperprolactinemia in alcoholic patients. ..
  28. CONST BIO RES FACIL: NEUROENDOCRINE
    DIPAK SARKAR; Fiscal Year: 2002
    ..abstract_text> ..
  29. Fetal Alcohol Effects on Circadian clocks and POMC
    DIPAK SARKAR; Fiscal Year: 2006
    ..This information should help to develop therapeutic strategies in managing sleep-wake disturbances and the resultant health consequences in FAE offspring [unreadable] [unreadable]..
  30. Fetal Alcohol Effects on Circadian clocks and POMC
    DIPAK KUMAR SARKAR; Fiscal Year: 2010
    ..This information should help to develop therapeutic strategies in managing sleep-wake disturbances and the resultant health consequences in FAE offspring. ..
  31. Model System Studies of Naltrexone and Alcohol Interaction
    DIPAK SARKAR; Fiscal Year: 2008
    ....
  32. Fetal Alcohol Effects on Circadian clocks and POMC
    DIPAK SARKAR; Fiscal Year: 2009
    ..This information should help to develop therapeutic strategies in managing sleep-wake disturbances and the resultant health consequences in FAE offspring. ..
  33. Biology of the NK cell cytolytic activity rhythm
    DIPAK KUMAR SARKAR; Fiscal Year: 2010
    ..The proposed series of studies should enhance our knowledge of the physiological mechanisms orchestrating NK cell circadian function. ..
  34. Fetal Alcohol Effects on Circadian clocks and POMC
    DIPAK SARKAR; Fiscal Year: 2009
    ..This information should help to develop therapeutic strategies in managing sleep-wake disturbances and the resultant health consequences in FAE offspring. ..
  35. Epigenetics of alcohol effects on stress axis development
    DIPAK SARKAR; Fiscal Year: 2008
    ....
  36. Biology of the NK cell cytolytic activity rhythm
    DIPAK SARKAR; Fiscal Year: 2009
    ..The proposed series of studies should enhance our knowledge of the physiological mechanisms orchestrating NK cell circadian function. ..
  37. ROLE OF OPIATES IN ALCOHOL-INDUCED NEUROTOXICITY
    DIPAK SARKAR; Fiscal Year: 2009
    ....
  38. Fetal Alcohol Effects on Circadian clocks and POMC
    DIPAK SARKAR; Fiscal Year: 2007
    ..This information should help to develop therapeutic strategies in managing sleep-wake disturbances and the resultant health consequences in FAE offspring. ..
  39. Fetal Alcohol Effects on Circadian clocks and POMC
    DIPAK SARKAR; Fiscal Year: 2008
    ..This information should help to develop therapeutic strategies in managing sleep-wake disturbances and the resultant health consequences in FAE offspring. ..
  40. OPIOID AND ALCOHOL REGULATED IMMUNE FUNCTION
    DIPAK SARKAR; Fiscal Year: 2002
    ....
  41. CONSTRUCTION OF BIOLOGY RESEARCH FACILITY
    DIPAK SARKAR; Fiscal Year: 2002
    ..abstract_text> ..
  42. ESTROGEN MITOGENIC ACTION IN THE PITUITARY
    DIPAK SARKAR; Fiscal Year: 2001
    ..Such knowledge should be important in understanding prolactinoma because increased proliferation is an early step in cell transformation.
  43. OPIOID AND ALCOHOL REGULATED IMMUNE FUNCTION
    DIPAK SARKAR; Fiscal Year: 2001
    ....
  44. ROLE OF OPIATES IN ALCOHOL-INDUCED NEUROTOXICITY
    DIPAK SARKAR; Fiscal Year: 2001
    ....
  45. ESTROGEN MITOGENIC ACTION IN THE PITUITARY
    DIPAK SARKAR; Fiscal Year: 2000
    ..Such knowledge should be important in understanding prolactinoma because increased proliferation is an early step in cell transformation.
  46. OPIOID AND ALCOHOL REGULATED IMMUNE FUNCTION
    DIPAK SARKAR; Fiscal Year: 2000
    ....
  47. ALCOHOL AND HYPERPROLACTINEMIA
    DIPAK SARKAR; Fiscal Year: 2000
    ..The proposed research will yield an increased understanding of ethanol effects on prolactinomas and hyperprolactinemia. Such knowledge should help to better manage these neuroendocrine diseases in alcoholic patients. ..
  48. ROLE OF OPIATES IN ALCOHOL-INDUCED NEUROTOXICITY
    DIPAK SARKAR; Fiscal Year: 2002
    ....
  49. ESTROGEN MITOGENIC ACTION IN THE PITUITARY
    DIPAK SARKAR; Fiscal Year: 2002
    ..Such knowledge should be important in understanding prolactinoma because increased proliferation is an early step in cell transformation.
  50. CONST BIO RES FACIL: ALCOHOL
    DIPAK SARKAR; Fiscal Year: 2002
    ..abstract_text> ..
  51. ROLE OF OPIATES IN ALCOHOL-INDUCED NEUROTOXICITY
    DIPAK SARKAR; Fiscal Year: 2004
    ....
  52. ALCOHOL AND HYPERPROLACTINEMIA
    DIPAK SARKAR; Fiscal Year: 1999
    ..The proposed research will yield an increased understanding of ethanol effects on prolactinomas and hyperprolactinemia. Such knowledge should help to better manage these neuroendocrine diseases in alcoholic patients. ..
  53. ALCOHOL AND HYPERPROLACTINEMIA
    DIPAK SARKAR; Fiscal Year: 2004
    ..Such knowledge will improve the understanding and management of hyperprolactinemia in alcoholic patients. ..
  54. ESTROGEN MITOGENIC ACTION IN THE PITUITARY
    DIPAK SARKAR; Fiscal Year: 2003
    ..Such knowledge should be important in understanding prolactinoma because increased proliferation is an early step in cell transformation.
  55. ROLE OF OPIATES IN ALCOHOL-INDUCED NEUROTOXICITY
    DIPAK SARKAR; Fiscal Year: 2003
    ....
  56. ALCOHOL AND HYPERPROLACTINEMIA
    DIPAK SARKAR; Fiscal Year: 2003
    ..Such knowledge will improve the understanding and management of hyperprolactinemia in alcoholic patients. ..
  57. OPIOID AND ALCOHOL REGULATED IMMUNE FUNCTION
    DIPAK SARKAR; Fiscal Year: 1999
    ....
  58. ROLE OF OPIATES IN ALCOHOL INDUCED NEUROTOXICITY
    DIPAK SARKAR; Fiscal Year: 2000
    ....
  59. INTERFERON GAMMA AND TUMOR GROWTH
    Gerard Doherty; Fiscal Year: 2002
    ..These experiments will elucidate the roles of IRF-1 and IRF-2 in tumor growth in intact, immunocompetent animals, and begin to address the potential clinical importance of IRF expression in human tumors. ..